ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Featured Science from ENDO 2020
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 175915" data-attributes="member: 13851"><p><span style="font-size: 26px"><strong>Three of the non-invasive methods used to predict who has NASH agree only about 20% of the time</strong></span></p><p></p><p><span style="color: rgb(184, 49, 47)">Researchers and clinicians have been trying to find a way to diagnose nonalcoholic steatohepatitis (NASH) without taking a liver tissue biopsy, but according to new research, formulas that aim to predict NASH based on risk factors do not agree with each other and their accuracy varies. </span>The <a href="https://www.endocrine.org/-/media/endocrine/files/endo2020/abstracts/friedman-abstract.pdf" target="_blank">study</a> was accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and publication in a special supplemental section of the <em>Journal of the Endocrine Society.</em></p><p></p><p><span style="color: rgb(184, 49, 47)">“The three non-invasive methods we investigated agreed on a NASH diagnosis for only about one-fifth of the participants in the database,” </span>said lead study author Theodore C. Friedman, M.D., Ph.D., chair of the Department of Internal Medicine of Charles R. Drew University of Medicine and Science in Los Angeles, Calif. <span style="color: rgb(184, 49, 47)">“These results imply that better methods are needed to predict NASH.” </span></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">SUN-606: </span>Identification of NASH Using Data from NHANES III</strong></p><p></p><p><span style="color: rgb(184, 49, 47)">Further refinement of a noninvasive method for identifying NASH is required. Considerable care must be taken in interpreting risk factors, because the results differ depending which method is used.</span> <span style="color: rgb(44, 130, 201)">This could have implications in clinical practice as well, where patients and their risk factors may be mis-identified if formulas are used and not liver biopsy. </span></p></blockquote><p></p>
[QUOTE="madman, post: 175915, member: 13851"] [SIZE=26px][B]Three of the non-invasive methods used to predict who has NASH agree only about 20% of the time[/B][/SIZE] [COLOR=rgb(184, 49, 47)]Researchers and clinicians have been trying to find a way to diagnose nonalcoholic steatohepatitis (NASH) without taking a liver tissue biopsy, but according to new research, formulas that aim to predict NASH based on risk factors do not agree with each other and their accuracy varies. [/COLOR]The [URL='https://www.endocrine.org/-/media/endocrine/files/endo2020/abstracts/friedman-abstract.pdf']study[/URL] was accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and publication in a special supplemental section of the [I]Journal of the Endocrine Society.[/I] [COLOR=rgb(184, 49, 47)]“The three non-invasive methods we investigated agreed on a NASH diagnosis for only about one-fifth of the participants in the database,” [/COLOR]said lead study author Theodore C. Friedman, M.D., Ph.D., chair of the Department of Internal Medicine of Charles R. Drew University of Medicine and Science in Los Angeles, Calif. [COLOR=rgb(184, 49, 47)]“These results imply that better methods are needed to predict NASH.” [/COLOR] [B][COLOR=rgb(184, 49, 47)]SUN-606: [/COLOR]Identification of NASH Using Data from NHANES III[/B] [COLOR=rgb(184, 49, 47)]Further refinement of a noninvasive method for identifying NASH is required. Considerable care must be taken in interpreting risk factors, because the results differ depending which method is used.[/COLOR] [COLOR=rgb(44, 130, 201)]This could have implications in clinical practice as well, where patients and their risk factors may be mis-identified if formulas are used and not liver biopsy. [/COLOR] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
X (Twitter)
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Featured Science from ENDO 2020
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top